In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Douglas E BiancurDepartment of Pathology, New York University Grossman School of Medicine; New York, NY 10016 USA.ORCID 0000-0001-8800-7124 Harsha VenkateshDepartment of Chemistry, New York University, New York, NY 10003, USA.
Yealeen JeongDepartment of Pathology, New York University Grossman School of Medicine; New York, NY 10016 USA.ORCID 0000-0002-7850-5418 Albert S W SohnPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.ORCID 0000-0001-7869-4362 Keisuke YamamotoPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.ORCID 0000-0002-6323-9540 Elaine Y LinPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.ORCID 0000-0003-3057-4163 Robert S BanhPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.ORCID 0000-0003-1959-4622 Mohamad AssiPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.
Beny ShapiroDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine; New York, New York 10016, USA.ORCID 0000-0002-1067-3458 Peter YuPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.ORCID 0000-0002-0384-9865 Soomin C SongDepartment of Pathology, New York University Grossman School of Medicine; New York, NY 10016 USA.ORCID 0000-0002-9581-0991 William A CoetzeeDepartment of Pathology, New York University Grossman School of Medicine; New York, NY 10016 USA.
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-0701-6203 Alec C KimmelmanPerlmutter Cancer Center, New York University Grossman School of Medicine; New York, NY 10016, USA.ORCID 0009-0002-9465-8411 Richard PossematoDepartment of Pathology, New York University Grossman School of Medicine; New York, NY 10016 USA.ORCID 0000-0002-2401-0030 Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7MIdentifying Metabolic Dependencies of Pancreatic CancersR35CA232124 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2018 to 2024
$6.5MRoles of Endothelial and Smooth Muscle KATP Channels in Myocardial Ischemic InjuryR01HL146514 · NHLBI · LSU HEALTH SCIENCES CENTER · PI COETZEE, WILLIAM A, LEFER, DAVID JOSEPH · 2020 to 2023
$3.0MFunctional interaction between cardiac Na channels and KATP channelsR01HL148609 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COETZEE, WILLIAM A, DELMAR, MARIO · 2020 to 2023
$2.7MFunctional Relevance of Pyrimidine Sensing and Response Pathways in Tumor Metabolism and Cancer TherapyR01CA286141 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Richard Lewis Possemato · 2024 to 2026
$2.7MK12 Training for Clinical and Translational Oncology ResearchersK12CA270377 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Janice M. Mehnert · 2023 to 2026
$2.2MTargeting Metabolic Liabilities in CancerR01CA214948 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI POSSEMATO, RICHARD LEWIS · 2018 to 2022
$1.9MRegulation Of Metabolism And Gene Expression By Iron-Sulfur Clusters - SupplementR01GM132491 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI POSSEMATO, RICHARD LEWIS · 2020 to 2023
$1.9MTargeting the autophagy-lysosome system to block pancreatic cancerR01CA251726 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERERA, RUSHIKA MIRIAM · 2021 to 2025
$1.8MElucidating The Adaptive Role Of Serine Codons During Pancreatic Tumorigenesis - Diversity SupplementR37CA289040 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Robert Singhung Banh · 2024 to 2026
$1.8MChemistry-Biology Interface Predoctoral Training ProgramT32GM158479 · NIGMS · NEW YORK UNIVERSITY · PI Paramjit S Arora, KEITH ALLEN WOERPEL · 2025 to 2026
$645kNCI NIH HHS K00 CA245822NCI NIH HHS K12 CA270377NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA214948NCI NIH HHS R01 CA251726NCI NIH HHS R01 CA286141NCI NIH HHS R35 CA232124NCI NIH HHS R37 CA289040NHLBI NIH HHS R01 HL146514NHLBI NIH HHS R01 HL148609NIGMS NIH HHS R01 GM132491NIGMS NIH HHS T32 GM158479
6 · The paper itselfAbstract
Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer that frequently presents with disseminated disease. The PDA metastatic microenvironment imposes distinct metabolic stressors, potentially generating context-dependent vulnerabilities. Therefore, we employed CRISPR-based genetic screening in a model of PDA liver metastasis to identify novel and possibly targetable liabilities. Remarkably, ferritin heavy chain (FTH1) emerged as the most prominent liver-specific dependency - loss of FTH1 suppressed tumor growth specifically in the liver microenvironment. FTH1 deletion and subsequent disruption of iron handling triggers mitochondrial dysfunction and ionic imbalance, including cytosolic calcium overload. These perturbations result in the activation of a transcriptional program that triggers anti-tumor immunity mediated by immunostimulatory cytokine IL36G. Mechanistically, FTH1 deletion and subsequent ionic imbalance causes decreased protein levels of the tumor suppressor
Indexed as
Carcinoma, Pancreatic DuctalInterleukinsIron OverloadPancreatic NeoplasmsProtein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsCell Line, TumorFerritinsGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMiceNeoplasm MetastasisSignal TransductionAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesFerritinsInterleukinsProtein Serine-Threonine KinasesSTK11 protein, humanStk11 protein, mouse
Identifiers
PMID42467776
PMCPMC13378540
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390